<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Recash test site | Owen Kent | Activity</title>
	<link>https://recash.wpsoul.net/members/tubalathe0/activity/</link>
	<atom:link href="https://recash.wpsoul.net/members/tubalathe0/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Owen Kent.</description>
	<lastBuildDate>Sun, 26 Jul 2026 04:41:35 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">fae301e38c6f0f39d503fa3757d779d6</guid>
				<title>Owen Kent posted an update: This study further confirmed that the introduction of [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/128323/</link>
				<pubDate>Mon, 30 Dec 2024 11:10:36 +0000</pubDate>

									<content:encoded><![CDATA[<p>This study further confirmed that the introduction of anti-inflammatory cytokine (IL-4) and cell adhesive motif (RGD) onto Ti substrate can work synergistically to generate a more favorable early-stage osteo-immune environment with superior osteogenic properties, thus representing a potential ideal surface for the generation of bone biomaterials.&hellip;<span class="activity-read-more" id="activity-read-more-128323"><a href="https://recash.wpsoul.net/activity/p/128323/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">bcab47aa79c69e2d38705c83a912126d</guid>
				<title>Owen Kent posted an update: ing position.In this paper, we describe a case series of four [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/122820/</link>
				<pubDate>Sat, 28 Dec 2024 12:25:15 +0000</pubDate>

									<content:encoded><![CDATA[<p>ing position.In this paper, we describe a case series of four patients who were admitted with emergencies related to aortic aneurysms over a 3-day period and were treated with endovascular repair. <a href="https://www.selleckchem.com/products/Isradipine(Dynacirc).html" rel="nofollow ugc">Isradipine</a> The first patient was an 81-year-old female with a history of abdominal pain and a ruptured aortic aneurysm diagnosed by AngioCT-scan. The&hellip;<span class="activity-read-more" id="activity-read-more-122820"><a href="https://recash.wpsoul.net/activity/p/122820/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3807ad4f32849d3047dbbe5b3be709be</guid>
				<title>Owen Kent posted an update: The frontline treatment options for patients with metastatic [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/116439/</link>
				<pubDate>Thu, 26 Dec 2024 11:25:59 +0000</pubDate>

									<content:encoded><![CDATA[<p>The frontline treatment options for patients with metastatic renal cell carcinoma (mRCC) are evolving rapidly since the approval of combination immunotherapies by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA). In particular, in combination with vascular endothelial growth factor receptor (VEGFR)&hellip;<span class="activity-read-more" id="activity-read-more-116439"><a href="https://recash.wpsoul.net/activity/p/116439/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ea2d255e852a74b0c6d20aa30b6abf7a</guid>
				<title>Owen Kent became a registered member</title>
				<link>https://recash.wpsoul.net/activity/p/98031/</link>
				<pubDate>Sat, 21 Dec 2024 00:25:50 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>